These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38554335)

  • 1. Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer.
    Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Kolsuz İ; Kıdı MM
    J Cancer Res Ther; 2024 Jan; 20(1):285-288. PubMed ID: 38554335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
    Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors.
    Ono T; Igawa S; Kurahayashi S; Okuma Y; Sugimoto A; Kusuhara S; Ozawa T; Fukui T; Sasaki J; Mitsufuji H; Yokoba M; Kubota M; Katagiri M; Naoki K
    Invest New Drugs; 2020 Jun; 38(3):885-893. PubMed ID: 32157598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
    Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
    Lin GN; Peng JW; Liu PP; Liu DY; Xiao JJ; Chen XQ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e189-e194. PubMed ID: 25359280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.
    Yucel S; Bilgin B
    J Oncol Pharm Pract; 2021 Jan; 27(1):71-77. PubMed ID: 32248739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
    Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil to lymphocyte ratio may predict efficacy of anti-PD-1 inhibitors in advanced EGFR-mutant non-small cell lung cancer: retrospective cohort study.
    Chen J; Zheng Q; Zhu S; Qiu D; Wang J
    Sci Rep; 2024 Feb; 14(1):4165. PubMed ID: 38378870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Chang YC; Lin MC
    PLoS One; 2015; 10(8):e0136252. PubMed ID: 26313661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of fibrinogen concentrations and the platelet-to-lymphocyte ratio predicts survival in patients with advanced lung adenocarcinoma treated with EGFR-TKIs.
    He Q; Li Y; Zhou X; Zhou W; Xia C; Zhang R; Zhang Z; Hu A; Peng S; Li J
    J Int Med Res; 2021 Apr; 49(4):3000605211004021. PubMed ID: 33794676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.